LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq:...
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic...
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq:...
LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.